BrightPath Biotherapeutics Co.Ltd. (JP:4594)

:4594

4594

BrightPath Biotherapeutics Co.Ltd.

RESEARCH TOOLSreports

Want to see JP:4594 full AI Analyst Report?

BrightPath Biotherapeutics Co.Ltd. (4594) Price & Analysis

0 Followers

4594 Stock Chart & Stats

¥48.00

¥1.00(2.27%)

At close: Jan 08 4:00 PM EST

¥48.00

¥1.00(2.27%)

Day’s Range― - ―

52-Week Range¥40.00 - ¥114.00

Previous CloseN/A

Volume188.00K

Average Volume (3M)2.78M

Market Cap

¥6.25B

Enterprise Value¥2.94B

Total Cash (Recent Filing)¥1.30B

Total Debt (Recent Filing)¥500.00M

Price to Earnings (P/E)―

Beta1.05

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-19.27

Shares Outstanding138,891,300

10 Day Avg. Volume4,086,650

30 Day Avg. Volume2,782,203

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)3.25

Price to Sales (P/S)91636.06

P/FCF Ratio-5.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Balance Sheet BufferVery low debt materially reduces refinancing and interest risk over the medium term, giving management optionality to fund R&D or seek partnerships without imminent creditor pressure. This structural strength lengthens runway relative to similarly loss-making peers and lowers near-term solvency risk.

Positive Gross Margin In 2025–2026A positive gross margin suggests the company can generate margin on product or milestone revenue, implying an underlying revenue model that can scale. If revenue stabilizes, this structural margin implies incremental sales could flow to operating leverage and support eventual profitability.

Narrowing Losses Vs. Earlier PeriodsTrend of narrowing losses indicates improving cost discipline or more efficient R&D spend, which is a durable operational improvement. Sustaining this trajectory can reduce funding needs, lower dilution risk, and make long-term planning and partnership discussions more viable.

Bears Say

Sustained Negative Cash Flow / Cash BurnConsistent negative operating and free cash flow at material levels is a structural drain on resources, forcing reliance on external financing or partnerships. Over 2–6 months this reduces strategic flexibility, raises dilution probability, and constrains the ability to scale R&D or commercial efforts without new capital.

Highly Volatile And Collapsed RevenueExtreme revenue volatility and a recent collapse signal weak commercial traction or lumpy non-recurring income. Structurally, this makes forecasting and funding of operations difficult, undermines stable cash flow generation, and raises execution risk for long-term commercialization plans.

Recurring Large Net Losses And Negative ROEPersistent, sizable net losses and negative ROE reflect a business not yet generating shareholder returns and relying on ongoing funding. Over months this perpetuates dilution risk, limits reinvestment capacity, and signals the company remains in an early, loss-making stage without proven path to sustained profitability.

4594 FAQ

What was BrightPath Biotherapeutics Co.Ltd.’s price range in the past 12 months?

BrightPath Biotherapeutics Co.Ltd. lowest stock price was ¥40.00 and its highest was ¥114.00 in the past 12 months.

What is BrightPath Biotherapeutics Co.Ltd.’s market cap?

BrightPath Biotherapeutics Co.Ltd.’s market cap is ¥6.25B.

When is BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date?

BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 55 days.

How were BrightPath Biotherapeutics Co.Ltd.’s earnings last quarter?

BrightPath Biotherapeutics Co.Ltd. released its earnings results on May 14, 2026. The company reported -¥2.63 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.63.

Is BrightPath Biotherapeutics Co.Ltd. overvalued?

According to Wall Street analysts BrightPath Biotherapeutics Co.Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BrightPath Biotherapeutics Co.Ltd. pay dividends?

BrightPath Biotherapeutics Co.Ltd. does not currently pay dividends.

What is BrightPath Biotherapeutics Co.Ltd.’s EPS estimate?

BrightPath Biotherapeutics Co.Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BrightPath Biotherapeutics Co.Ltd. have?

BrightPath Biotherapeutics Co.Ltd. has 138,891,300 shares outstanding.

What happened to BrightPath Biotherapeutics Co.Ltd.’s price movement after its last earnings report?

BrightPath Biotherapeutics Co.Ltd. reported an EPS of -¥2.63 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.455%.

Which hedge fund is a major shareholder of BrightPath Biotherapeutics Co.Ltd.?

Currently, no hedge funds are holding shares in JP:4594

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

BrightPath Biotherapeutics Co.Ltd.

BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.